BN
BusinessAI Desk•2 views

Sun Pharma to Buy Organon in $11.75B Deal

Indian pharmaceutical giant Sun Pharmaceutical Industries is acquiring U.S.-based Organon & Co in an all-cash deal valued at $11.75 billion. Sun Pharma will purchase all outstanding shares at $14 per share. This strategic acquisition is designed to bolster Sun Pharma's innovative medicines division and enhance its global footprint. Analysts anticipate the deal will lift Sun Pharma into the top 25 global pharmaceutical companies. Organon specializes in women's health and biosimilars, providing complementary assets and access to key markets like the U.S. and Europe.

Ad slot
Sun Pharma to Buy Organon in $11.75B Deal

Indian drugmaker Sun Pharmaceutical Industries is set to acquire U.S. firm Organon & Co in an all-cash transaction valued at $11.75 billion.

Transaction Details

The acquisition involves Sun Pharma purchasing all outstanding shares of Organon for $14 per share. This deal, which includes debt, values the New Jersey-based company at $11.75 billion.

  • Acquirer: Sun Pharmaceutical Industries (India)
  • Target: Organon & Co (USA)
  • Deal Value: $11.75 billion (all-cash)
  • Price per Share: $14

Strategic Rationale and Market Impact

Sun Pharma stated that this buyout is a key component of its strategy to expand its Innovative Medicines business. The acquisition is expected to significantly boost Sun Pharma's global standing.

Ad slot
  • Global Ranking Boost: The deal is projected to elevate Sun Pharma, India's largest drug manufacturer, into the top 25 global pharmaceutical companies, with an anticipated revenue of $12.4 billion.
  • Complementary Strengths: Dilip Shanghvi, executive chairman of Sun Pharma, noted that Organon's portfolio, capabilities, and global reach are highly complementary to Sun Pharma's existing operations.
  • Market Focus: Organon specializes in women's health and biosimilars, offering over 70 products sold in 140 countries. Its key markets include the U.S., Europe, China, Canada, and Brazil.

Financial Implications

The merger is expected to strengthen Sun Pharma's innovative medicine segment:

  • In the financial year ending March 2025, the innovative medicine segment accounted for 20% of Sun Pharma's total sales.
  • Following the acquisition, this segment is projected to contribute 27% to the company's top line.

Company Statements

  • Carrie Cox, executive chair at Organon, stated that the all-cash transaction offered "compelling and immediate value to Organon stockholders" following a review of strategic alternatives.
  • Kirti Ganorkar, managing director at Sun Pharma, described the transaction as a "logical next step in strengthening Sun Pharma's global business," particularly by scaling medicine products in the U.S. market.
Ad slot